IN2014DN11155A - - Google Patents

Info

Publication number
IN2014DN11155A
IN2014DN11155A IN11155DEN2014A IN2014DN11155A IN 2014DN11155 A IN2014DN11155 A IN 2014DN11155A IN 11155DEN2014 A IN11155DEN2014 A IN 11155DEN2014A IN 2014DN11155 A IN2014DN11155 A IN 2014DN11155A
Authority
IN
India
Prior art keywords
patient
car
cell
domain
line
Prior art date
Application number
Inventor
Carl H June
Bruce L Levine
Michael D Kalos
Stephan Grupp
Original Assignee
Univ Pennsylvania
Philadelphia Children Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49916566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN11155(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Pennsylvania, Philadelphia Children Hospital filed Critical Univ Pennsylvania
Publication of IN2014DN11155A publication Critical patent/IN2014DN11155A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Computational Biology (AREA)

Abstract

The present invention provides compositions and methods for treating cancer in a patient. In one embodiment the method comprises a first line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain a transmembrane domain a costimulatory signaling region and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second line of therapy appropriate for treating the patient as a consequence of the presence of the CAR T cell in the patient.
IN11155DEN2014 2012-07-13 2013-07-12 IN2014DN11155A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261671482P 2012-07-13 2012-07-13
US201361782982P 2013-03-14 2013-03-14
PCT/US2013/050267 WO2014011984A1 (en) 2012-07-13 2013-07-12 Toxicity management for anti-tumor activity of cars

Publications (1)

Publication Number Publication Date
IN2014DN11155A true IN2014DN11155A (en) 2015-10-02

Family

ID=49916566

Family Applications (1)

Application Number Title Priority Date Filing Date
IN11155DEN2014 IN2014DN11155A (en) 2012-07-13 2013-07-12

Country Status (22)

Country Link
US (4) US20150202286A1 (en)
EP (4) EP4019041B1 (en)
JP (5) JP6382191B2 (en)
KR (1) KR102204029B1 (en)
CN (4) CN111481667A (en)
AU (2) AU2013289967B2 (en)
BR (1) BR112015000660A8 (en)
CA (1) CA2878928C (en)
DK (3) DK2872171T3 (en)
EA (1) EA201590210A1 (en)
ES (3) ES2941370T3 (en)
FI (1) FI4019041T3 (en)
HK (1) HK1253365A1 (en)
HR (1) HRP20230297T1 (en)
HU (3) HUE061555T2 (en)
IN (1) IN2014DN11155A (en)
LT (3) LT4019041T (en)
MX (2) MX2015000438A (en)
PL (2) PL4019041T3 (en)
PT (3) PT3338794T (en)
SI (1) SI4019041T1 (en)
WO (1) WO2014011984A1 (en)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014011984A1 (en) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Toxicity management for anti-tumor activity of cars
WO2014130635A1 (en) 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
RU2708032C2 (en) 2013-02-20 2019-12-03 Новартис Аг CANCER TREATMENT USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANISED ANTI-EGFRvIII ANTIBODY
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
UY35468A (en) 2013-03-16 2014-10-31 Novartis Ag CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
CA3225453A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
WO2015112626A1 (en) 2014-01-21 2015-07-30 June Carl H Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
HUE054588T2 (en) 2014-04-07 2021-09-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
WO2015164354A1 (en) * 2014-04-21 2015-10-29 The Childen's Hospital Of Philadelphia Compositions and methods for treating cytokine-related disorders
CA2955154C (en) 2014-07-21 2023-10-31 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
AR101829A1 (en) 2014-07-21 2017-01-18 Novartis Ag CANCER TREATMENT USING A CLL-1 CHEMERIC ANTIGEN RECEIVER
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
PL3183268T3 (en) 2014-08-19 2020-09-07 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
WO2016044605A1 (en) 2014-09-17 2016-03-24 Beatty, Gregory Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
KR20170068504A (en) * 2014-10-08 2017-06-19 노파르티스 아게 Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
IL253149B2 (en) 2014-12-29 2023-11-01 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2016115482A1 (en) 2015-01-16 2016-07-21 Novartis Pharma Ag Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
SI3253865T1 (en) * 2015-02-06 2022-10-28 National University Of Singapore Methods for enhancing efficacy of therapeutic immune cells
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
IL284985B2 (en) * 2015-02-18 2023-03-01 Enlivex Therapeutics R& D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
EP4056588A1 (en) 2015-04-08 2022-09-14 Novartis AG Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell
CA2982996A1 (en) 2015-04-17 2016-10-20 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
KR20170138534A (en) 2015-04-21 2017-12-15 엔리벡스 테라퓨틱스 리미티드 Therapeutically Administered Blood Apoptosis Cell Preparations and Uses Thereof
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
CN108780084B (en) * 2015-09-03 2022-07-22 诺华股份有限公司 Biomarkers predictive of cytokine release syndrome
MA44909A (en) 2015-09-15 2018-07-25 Acerta Pharma Bv THERAPEUTIC ASSOCIATION OF A CD19 INHIBITOR AND A BTK INHIBITOR
EP3708588A1 (en) 2015-11-27 2020-09-16 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
US11815514B2 (en) 2015-12-04 2023-11-14 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
JP7082055B2 (en) 2015-12-22 2022-06-07 ノバルティス アーゲー Antibodies to Mesothelin Chimeric Antigen Receptor (CAR) and PD-L1 Inhibitors for Combined Use in Anticancer Treatment
JP6853514B2 (en) * 2015-12-27 2021-03-31 国立大学法人東海国立大学機構 Chimeric antigen receptor genetically modified lymphocytes that suppress the production of inflammatory cytokines
EP3416661A4 (en) * 2016-02-18 2020-03-04 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
EP4015536A1 (en) 2016-03-22 2022-06-22 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Early intervention methods to prevent or ameliorate toxicity
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
JP7145761B2 (en) 2016-04-22 2022-10-03 クレイジュ・メディカル・カンパニー・リミテッド Cellular Immunotherapy Compositions and Methods
WO2017189959A1 (en) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448987A4 (en) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. Compositions for the treatment of disease
MA45341A (en) * 2016-06-06 2019-04-10 Hutchinson Fred Cancer Res METHODS FOR TREATING B-LYMPHOCYTE MALIGNITIES USING ADOPTIVE CELL THERAPY
EP3472318B1 (en) * 2016-07-08 2023-09-06 Exuma Biotech Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
JP7219376B2 (en) 2016-07-15 2023-02-08 ノバルティス アーゲー Treatment and prevention of cytokine release syndrome using chimeric antigen receptors in combination with kinase inhibitors
EP3490590A2 (en) * 2016-08-01 2019-06-05 Novartis AG Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
CN117866991A (en) 2016-10-07 2024-04-12 诺华股份有限公司 Chimeric antigen receptor for the treatment of cancer
CN106636090B (en) * 2016-10-11 2019-08-09 上海优卡迪生物医药科技有限公司 SiRNA, recombinant expression CAR-T carrier and its construction method of human leukocyte interleukin 6 and application
EP3548046A2 (en) 2016-12-03 2019-10-09 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
MA46963A (en) * 2016-12-03 2019-10-09 Juno Therapeutics Inc METHODS FOR DETERMINING THE DOSAGE OF CAR-T CELLS
CN108148863B (en) * 2016-12-05 2019-12-17 上海优卡迪生物医药科技有限公司 CAR-T transgenic vector for blocking IL6R and relieving CRS (cell-specific receptor), and construction method and application thereof
CN108250301A (en) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 A kind of multiple target point Chimeric antigen receptor
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
CN110612119A (en) 2017-02-07 2019-12-24 西雅图儿童医院（Dba西雅图儿童研究所） Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
US20200191774A1 (en) * 2017-02-27 2020-06-18 Juno Therapeutics, Inc. Compositions, articles of manufacture and methods related to dosing in cell therapy
JP7178355B2 (en) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Compositions and methods for CAR T cell therapy
RU2019133280A (en) 2017-03-22 2021-04-22 Новартис Аг COMPOSITIONS AND METHODS FOR IMMUNO ONCOLOGY
AR111651A1 (en) 2017-04-28 2019-08-07 Novartis Ag CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES
US20200333329A1 (en) * 2017-05-01 2020-10-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Targeted cytokine blockades for car-t therapy
CN111225675B (en) 2017-06-02 2024-05-03 朱诺治疗学股份有限公司 Articles and methods of treatment using adoptive cell therapy
KR20200014418A (en) * 2017-06-08 2020-02-10 엔리벡스 테라퓨틱스 리미티드 Therapeutic Apoptosis Cells for Cancer Therapy
US20190038733A1 (en) 2017-08-10 2019-02-07 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
EP3691663A4 (en) * 2017-10-02 2021-08-18 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a gm-csf antagonist
KR20200086278A (en) 2017-10-18 2020-07-16 노파르티스 아게 Compositions and methods for selective proteolysis
KR20230011487A (en) * 2017-10-18 2023-01-20 카이트 파마 인코포레이티드 Methods of administering chimeric antigen receptor immunotherapy
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
JP2021512147A (en) 2018-01-22 2021-05-13 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． How to use CAR T cells
CN108300807A (en) * 2018-02-07 2018-07-20 安徽古生物科技有限公司 For the method for forth generation Chimeric antigen receptor CAR carriers PCR identifications
US20210046159A1 (en) * 2018-03-09 2021-02-18 Ospedale San Raffaele S.R.L. Il-1 antagonist and toxicity induced by cell therapy
WO2019178259A2 (en) * 2018-03-14 2019-09-19 Celledit Llc Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US20210213063A1 (en) 2018-05-25 2021-07-15 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
MX2020013017A (en) 2018-06-01 2021-03-02 Mayo Found Medical Education & Res Materials and methods for treating cancer.
AU2019284911A1 (en) 2018-06-13 2020-12-17 Novartis Ag BCMA chimeric antigen receptors and uses thereof
CA3107383A1 (en) 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
CN108949759B (en) * 2018-07-23 2021-06-01 合肥一兮生物科技有限公司 siRNA for knocking down human IL-15, CD19CAR expression vector, CAR-T cell, construction method and application
KR20210043623A (en) * 2018-08-10 2021-04-21 주식회사 유틸렉스 Chimeric antigen receptor and CAR-T cells that bind to HLA-DR
US20220348682A1 (en) 2018-08-30 2022-11-03 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
AU2019340662A1 (en) * 2018-09-10 2021-05-06 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
CA3116412A1 (en) * 2018-10-31 2020-05-07 Humanigen, Inc. Materials and methods for treating cancer
BR112021009420A2 (en) * 2018-11-16 2021-11-23 Juno Therapeutics Inc Engineered t-cell dosing methods for the treatment of b-cell malignancies
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
EP3893899A2 (en) 2018-12-12 2021-10-20 Kite Pharma, Inc. Chimeric antigen receptors and car-t cells and methods of use
EP3908613A4 (en) * 2019-01-07 2022-10-19 Celluris Participações Ltda. Bispecific in tandem receptor car and method for modulating the tumoral microenvironment
CN112430579A (en) * 2019-08-26 2021-03-02 深圳宾德生物技术有限公司 Chimeric antigen receptor T cell targeting Her2 and interfering IL-6 expression, and preparation method and application thereof
CN114945382A (en) 2019-11-26 2022-08-26 诺华股份有限公司 CD19 and CD22 chimeric antigen receptors and uses thereof
EP4106774A1 (en) * 2020-02-20 2022-12-28 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
EP3988116A1 (en) * 2020-10-23 2022-04-27 Consejo Superior De Investigaciones Científicas (CSIC) Methods and compositions for the treatment of hematologic malignancies
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
TW202237638A (en) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
AR124414A1 (en) 2020-12-18 2023-03-22 Century Therapeutics Inc CHIMERIC ANTIGEN RECEPTOR SYSTEM WITH ADAPTABLE RECEPTOR SPECIFICITY
KR20230157315A (en) 2021-01-28 2023-11-16 리제너론 파마슈티칼스 인코포레이티드 Compositions and methods for treating cytokine release syndrome
WO2023004055A1 (en) * 2021-07-21 2023-01-26 The Cleveland Clinic Foundation Metabolic and inflammatory markers for car-t cell therapy
US20230296610A1 (en) * 2022-02-15 2023-09-21 Kite Pharma, Inc. Predicting adverse events from immunotherapy
WO2024084518A1 (en) * 2022-10-20 2024-04-25 Microcrispr Pvt Ltd. Attenuation of cytokine release syndrome in immunotherapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ATE195022T1 (en) 1987-04-27 2000-08-15 Unilever Nv SPECIFIC BINDING TESTING METHODS
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US6267722B1 (en) 1998-02-03 2001-07-31 Adeza Biomedical Corporation Point of care diagnostic systems
US6656745B1 (en) 2000-06-02 2003-12-02 Francis X. Cole Devices and methods for a multi-level, semi-quantitative immunodiffusion assay
AU2008207646A1 (en) * 2001-10-04 2008-09-25 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
MXPA06002853A (en) * 2003-09-11 2006-06-14 Kemia Inc Cytokine inhibitors.
JP4711963B2 (en) * 2003-09-15 2011-06-29 オクラホマ メディカル リサーチ ファウンデーション Methods using cytokine assays to diagnose, treat and evaluate inflammatory and autoimmune diseases
US7189522B2 (en) 2005-03-11 2007-03-13 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
CA2688146C (en) 2007-05-21 2018-03-06 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
WO2008157282A1 (en) * 2007-06-18 2008-12-24 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
WO2010065079A2 (en) * 2008-11-25 2010-06-10 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
US9452227B2 (en) * 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
WO2010075249A2 (en) * 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
EP2504031A4 (en) 2009-11-24 2013-06-26 Alderbio Holdings Llc Antibodies to il-6 and use thereof
BR122021026169B1 (en) * 2010-12-09 2023-12-12 The Trustees Of The University Of Pennsylvania USE OF A CELL
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
EP2872717B1 (en) 2012-07-04 2017-06-28 In & Tec S.r.l. Hinge for rotatably moving a door, in particular a reinforced door
WO2014011984A1 (en) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Toxicity management for anti-tumor activity of cars

Also Published As

Publication number Publication date
CN111481667A (en) 2020-08-04
JP2015522081A (en) 2015-08-03
LT4019041T (en) 2023-04-11
DK4019041T3 (en) 2023-04-03
AU2018203924B2 (en) 2020-04-16
DK3338794T3 (en) 2020-05-04
HK1253365A1 (en) 2019-06-14
JP2019006782A (en) 2019-01-17
HUE061555T2 (en) 2023-07-28
AU2013289967B2 (en) 2018-03-29
PL4019041T3 (en) 2023-05-08
BR112015000660A2 (en) 2014-01-16
US11273219B2 (en) 2022-03-15
CA2878928C (en) 2023-03-14
JP2018150320A (en) 2018-09-27
EP4019041B1 (en) 2022-12-28
LT3338794T (en) 2020-05-25
HUE048947T2 (en) 2020-09-28
JP7034125B2 (en) 2022-03-11
FI4019041T3 (en) 2023-04-03
CN104427997A (en) 2015-03-18
PL2872171T3 (en) 2021-07-12
MX2019014761A (en) 2020-02-12
ES2941370T3 (en) 2023-05-22
EP3338794B1 (en) 2020-02-26
EA201590210A1 (en) 2015-08-31
AU2013289967A1 (en) 2015-01-22
HUE053556T2 (en) 2021-07-28
KR20150042784A (en) 2015-04-21
KR102204029B1 (en) 2021-01-19
ES2778701T3 (en) 2020-08-11
DK2872171T3 (en) 2021-03-08
CN111467494B (en) 2023-05-02
US10603378B2 (en) 2020-03-31
PT4019041T (en) 2023-03-29
CN111467494A (en) 2020-07-31
PT3338794T (en) 2020-04-24
PT2872171T (en) 2021-03-31
US20180243411A1 (en) 2018-08-30
EP3338794A1 (en) 2018-06-27
CN104427997B (en) 2020-12-11
EP4019041A1 (en) 2022-06-29
MX2015000438A (en) 2016-04-25
JP6382191B2 (en) 2018-08-29
JP2019182874A (en) 2019-10-24
CA2878928A1 (en) 2014-01-16
ES2859522T3 (en) 2021-10-04
US20180256712A1 (en) 2018-09-13
US20230013642A1 (en) 2023-01-19
JP6563554B2 (en) 2019-08-21
CN108379586A (en) 2018-08-10
HRP20230297T1 (en) 2023-05-12
EP2872171A4 (en) 2016-02-10
EP3721901A1 (en) 2020-10-14
US20150202286A1 (en) 2015-07-23
EP2872171A1 (en) 2015-05-20
SI4019041T1 (en) 2023-04-28
JP2022066304A (en) 2022-04-28
WO2014011984A1 (en) 2014-01-16
AU2018203924A1 (en) 2018-06-21
EP2872171B1 (en) 2021-01-06
LT2872171T (en) 2021-04-26
BR112015000660A8 (en) 2022-03-15

Similar Documents

Publication Publication Date Title
IN2014DN11155A (en)
MX2018009820A (en) Use of cart19 to deplete normal b cells to induce tolerance.
MX2020005143A (en) Use of chimeric antigen receptor-modified t cells to treat cancer.
IN2014DN06522A (en)
MX2018005618A (en) Chimeric receptors containing traf-inducing domains and related compositions and methods.
TN2015000050A1 (en) Methods of treating a tauopathy
MX2014010181A (en) Use of icos-based cars to enhance antitumor activity and car persistence.
MX2016004362A (en) Chimeric antigen receptor.
MX2021010672A (en) Diagnosis and therapy of cancer involving cancer stem cells.
MY190711A (en) Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
MX2021015735A (en) Therapeutic nuclease compositions and methods.
MY165499A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
MX2015003968A (en) Angiotensin in treating brain conditions.
GB2534478A (en) Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10
TN2013000246A1 (en) Use of chimeric antigen receptor-modified t cells to treat cancer
TN2013000433A1 (en) Therapeutic nuclease compositions and methods
TN2014000207A1 (en) Anti il-36r antibodies